PDCD1 and cancer: Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (PD-1) and anti-programmed death-ligand 1 (PD-L1) antibodies, have revolutionised the treatment of various cancers owing to their potent therapeutic efficacy1,2.